BRPI0619868A8 - Dispersão sólida compreendendo um ingrediente ativo tendo um ponto de fusão baixo e comprimido para administração oral compreendendo o mesmo - Google Patents

Dispersão sólida compreendendo um ingrediente ativo tendo um ponto de fusão baixo e comprimido para administração oral compreendendo o mesmo

Info

Publication number
BRPI0619868A8
BRPI0619868A8 BRPI0619868A BRPI0619868A BRPI0619868A8 BR PI0619868 A8 BRPI0619868 A8 BR PI0619868A8 BR PI0619868 A BRPI0619868 A BR PI0619868A BR PI0619868 A BRPI0619868 A BR PI0619868A BR PI0619868 A8 BRPI0619868 A8 BR PI0619868A8
Authority
BR
Brazil
Prior art keywords
solid dispersion
active ingredient
melting point
oral administration
same
Prior art date
Application number
BRPI0619868A
Other languages
English (en)
Inventor
Wook Kim Sang
Gi Yi Hong
Kuk Ryu Jae
Soo Woo Jong
Original Assignee
Hanmi Pharm Ind Co Ltd
Hanmi Holdings Co Ltd
Hanmi Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd, Hanmi Holdings Co Ltd, Hanmi Science Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of BRPI0619868A2 publication Critical patent/BRPI0619868A2/pt
Publication of BRPI0619868A8 publication Critical patent/BRPI0619868A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

DISPERSÃO SÓLIDA COMPREENDENDO UM INGREDIENTE ATIVO TENDO UM PONTO DE FUSÃO BAIXO E COMPRIMIDO PARA ADMINISTRAÇÃO ORAL COMPREENDENDO O MESMO Uma dispersão sólida fundida que compreende um ingrediente ativo que tem um ponto de fusão de 80C ou inferior e um absorvente farmaceuticamente aceitável que tem uma área de superfície específica que varia de 20 a 400 m2/g, pode ser convenientemente comprimida em um comprimido sem gerar os problemas de descabeçamento e aderência, e um comprimido compreendendo a referida dispersão sólida fundida pode manter uma taxa de liberação uniforme durante um tempo prolongado quando oralmente administrado.
BRPI0619868A 2005-12-16 2006-12-18 Dispersão sólida compreendendo um ingrediente ativo tendo um ponto de fusão baixo e comprimido para administração oral compreendendo o mesmo BRPI0619868A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20050124386 2005-12-16
KR10-2005-0124386 2005-12-16
PCT/KR2006/005526 WO2007069874A1 (en) 2005-12-16 2006-12-18 Solid dispersion comprising an active ingredient having a low melting point and tablet for oral administration comprising same

Publications (2)

Publication Number Publication Date
BRPI0619868A2 BRPI0619868A2 (pt) 2011-10-25
BRPI0619868A8 true BRPI0619868A8 (pt) 2016-06-07

Family

ID=38163142

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0619868A BRPI0619868A8 (pt) 2005-12-16 2006-12-18 Dispersão sólida compreendendo um ingrediente ativo tendo um ponto de fusão baixo e comprimido para administração oral compreendendo o mesmo

Country Status (15)

Country Link
US (1) US20080292702A1 (pt)
EP (1) EP1968542B1 (pt)
JP (1) JP2009519326A (pt)
CN (1) CN101330904B (pt)
AU (1) AU2006325658B2 (pt)
BR (1) BRPI0619868A8 (pt)
CA (1) CA2633266C (pt)
ES (1) ES2429097T3 (pt)
HK (1) HK1126671A1 (pt)
IL (1) IL191804A0 (pt)
NO (1) NO339674B1 (pt)
NZ (1) NZ569813A (pt)
RU (1) RU2403013C2 (pt)
WO (1) WO2007069874A1 (pt)
ZA (1) ZA200806138B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004272111A1 (en) 2003-09-11 2005-03-24 Xenoport, Inc. Treating and/or preventing urinary incontinence using prodrugs of GABA analogs
KR101067224B1 (ko) * 2008-07-22 2011-09-22 한국콜마 주식회사 이부프로펜 함유 서방출성 시럽제 및 그의 제조방법
KR101005391B1 (ko) * 2008-07-22 2010-12-30 한국콜마 주식회사 덱시부프로펜 함유 서방출성 시럽제 및 그의 제조방법
CN101961306B (zh) * 2009-07-24 2011-11-09 北京化工大学 一种低熔点药物固体分散体的制备方法
CN102144982B (zh) * 2011-03-30 2012-12-12 江苏神龙药业有限公司 一种米诺膦酸片及其制备方法
CN102406940B (zh) * 2011-11-01 2013-07-03 温州大学 一种纳米级片状羧甲基淀粉钠在固体分散体中的应用
WO2013154511A1 (en) * 2012-04-13 2013-10-17 Mahmut Bilgic Film tablet formulations comprising dexibuprofen
UY36046A (es) 2014-03-26 2015-10-30 Millennium Pharm Inc Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
JP6647902B2 (ja) * 2015-10-30 2020-02-14 株式会社ファンケル 徐放性顆粒剤
CN106265522A (zh) * 2016-08-30 2017-01-04 铜陵翔宇商贸有限公司 布洛芬‑pvp共沉淀物及其制备方法
JP7109255B2 (ja) * 2017-05-23 2022-07-29 ライオン株式会社 粉砕物の製造方法及び錠剤の製造方法
JP7147262B2 (ja) 2017-05-23 2022-10-05 大正製薬株式会社 固形製剤
CN110621305A (zh) * 2017-07-24 2019-12-27 爱科思华制药研发有限责任公司 高载药量药物组合物
RU2685294C1 (ru) * 2018-05-10 2019-04-17 Общество с ограниченной ответственностью "ДИНОН" (ООО "ДИНОН") Поглотитель, способ его приготовления (варианты) и способ удаления диоксида углерода из газовых смесей
CN112263567B (zh) * 2020-10-19 2022-05-03 南京易亨制药有限公司 一种布洛芬缓释胶囊及制备方法
CN117363320B (zh) * 2023-12-07 2024-02-13 黑龙江省鑫博鑫交通科技有限公司 一种公路用融雪剂及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56120616A (en) * 1980-02-27 1981-09-22 Kaken Pharmaceut Co Ltd Ibuprofen-containing granule, its preparation, and internal medicine comprising it
GB8601204D0 (en) * 1986-01-18 1986-02-19 Boots Co Plc Therapeutic agents
CH669523A5 (pt) * 1986-06-25 1989-03-31 Mepha Ag
US4806359A (en) * 1987-04-22 1989-02-21 Mcneilab, Inc. Iburprofen sustained release matrix and process
DE19509807A1 (de) * 1995-03-21 1996-09-26 Basf Ag Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
IE80467B1 (en) * 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
US6391338B1 (en) * 1995-09-07 2002-05-21 Biovail Technologies Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
IL123505A (en) * 1996-07-08 2004-12-15 Penwest Pharmaceuticals Compan Sustained release matrix for high-dose insoluble drugs
US6787157B1 (en) * 1998-03-10 2004-09-07 Abbott Laboratories Multiphase active ingredient-containing formulations
US6183779B1 (en) * 1999-03-22 2001-02-06 Pharmascience Inc. Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin
BR0016236A (pt) * 1999-12-09 2002-12-24 Boots Co Plc Agentes terapêuticos
GB0113839D0 (en) * 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents

Also Published As

Publication number Publication date
NZ569813A (en) 2011-07-29
BRPI0619868A2 (pt) 2011-10-25
CN101330904A (zh) 2008-12-24
EP1968542A1 (en) 2008-09-17
AU2006325658B2 (en) 2010-04-08
EP1968542B1 (en) 2013-08-14
HK1126671A1 (en) 2009-09-11
EP1968542A4 (en) 2010-06-02
CA2633266A1 (en) 2007-06-21
US20080292702A1 (en) 2008-11-27
CA2633266C (en) 2011-08-02
AU2006325658A1 (en) 2007-06-21
CN101330904B (zh) 2012-04-18
NO339674B1 (no) 2017-01-23
JP2009519326A (ja) 2009-05-14
IL191804A0 (en) 2008-12-29
ZA200806138B (en) 2009-11-25
ES2429097T3 (es) 2013-11-13
NO20083151L (no) 2008-09-05
WO2007069874A1 (en) 2007-06-21
RU2403013C2 (ru) 2010-11-10
RU2008129041A (ru) 2010-01-27

Similar Documents

Publication Publication Date Title
BRPI0619868A8 (pt) Dispersão sólida compreendendo um ingrediente ativo tendo um ponto de fusão baixo e comprimido para administração oral compreendendo o mesmo
RS51961B (en) APPLICATION OF FLIBANSERINE FOR TREATMENT OF SEXUAL DESIRE DISORDERS IN PREMENOPAUSE
BR112012007412A2 (pt) tabletes transformáveis de forma oral.
MX2010005175A (es) Comprimido dispersable oral.
CY1112517T1 (el) Φαρμακοτεχνικες μορφες τροποποιημενης αποδεσμευσης μιας τουλαχιστον μορφης τραμαδολης
RS20060140A (en) Solid pharmaceutical dosage form
MX2009004861A (es) Forma de dosificacion farmaceutica para la administracion oral de inhibidor de tirosina quinasa.
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
GEP20125701B (en) Application of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile
BRPI0508251A (pt) métodos para o tratamento de tinido auditivo induzido por excitotoxicidade coclear
NZ581176A (en) Stabilized amorphous forms of imatinib mesylate the formulation is a solid dispersion
CL2018001420A1 (es) Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma. (divisional solicitud 201701853)
RS52421B (en) RAZAGILIN FORMULATION WITH DELAYED RELEASE
NZ598744A (en) (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
UA90858C2 (ru) Композиция с контролируемым высвобождением варденафила
ITMI20011337A0 (it) Composizioni farmaceutiche orali a rilascio modificato del principio attivo
SG10201407947WA (en) Compressible-coated pharmaceutical compositions and tablets and methods of manufacture
RS54398B1 (en) THE USE OF FLIBANSERINE FOR THE TREATMENT OF SEXUAL DESIRE DISORDERS IN POSTMENOPAUSE
MY162494A (en) Solid pharmaceutical compositions containing an integrase inhibitor
CO6150126A2 (es) Formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina
EA200001201A3 (ru) Таблетка с основой, позволяющая осуществлять пролонгированное высвобождение триметазидина после введения оральным путем
MX2021004457A (es) Composicion farmaceutica para administracion oral que comprende derivado de aminopirimidina o su sal.
BRPI0414305A (pt) sistema de liberação de drogas por via oral
BRPI0412364A (pt) composição farmacêutica sólida, compreendendo amisulpride
AR038206A1 (es) Composicion farmaceutica dispersable oralmente de ivabradina

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: HANMI HOLDINGS CO., LTD. (KR)

Free format text: TRANSFERIDO DE: HANMI PHARM. CO., LTD.

B25D Requested change of name of applicant approved

Owner name: HANMI SCIENCE CO., LTD. (KR)

B25G Requested change of headquarter approved

Owner name: HANMI SCIENCE CO., LTD. (KR)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2494 DE 23-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.